Compare NC & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NC | PROF |
|---|---|---|
| Founded | 1913 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Coal Mining | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.7M | 248.8M |
| IPO Year | 2006 | 2017 |
| Metric | NC | PROF |
|---|---|---|
| Price | $38.66 | $5.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 15.1K | ★ 120.7K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.07% | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $104,778,000.00 | $16,098,000.00 |
| Revenue This Year | N/A | $92.40 |
| Revenue Next Year | N/A | $64.10 |
| P/E Ratio | $38.17 | ★ N/A |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $39.69 | $3.92 |
| 52 Week High | $59.42 | $8.95 |
| Indicator | NC | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 29.23 | 27.52 |
| Support Level | N/A | $4.97 |
| Resistance Level | $44.04 | $6.06 |
| Average True Range (ATR) | 1.25 | 0.35 |
| MACD | -0.11 | -0.10 |
| Stochastic Oscillator | 1.25 | 16.23 |
NACCO Industries Inc is a holding company that operates in the mining and natural resource industries. It has three operating segments: Utility Coal Mining, Contract Mining, and Minerals and Royalties. The Utility Coal Mining segment, operated by North American Coal, manages surface coal mines that are exclusive, long-term fuel providers for power generation companies. The Contract Mining segment, operated by North American Mining, is a provider of a broad range of specialized, long-term contract mining services. The Minerals and Royalties segment, which includes the Catapult Mineral Partners (Catapult) business, acquires and promotes the development of mineral and royalty interests and other related investments.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.